Publication & Citation Trends
Publications
0 total
Discovery of a Potent and Selective Covalent p300/CBP Inhibitor. OA
Cited by 20
Semantic Scholar
Discovery of Spirohydantoins as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases. OA
Cited by 16
Semantic Scholar
Corrigendum to "Investigation of biaryl heterocycles as inhibitors of Wee1 kinase" [Bioorg. Med. Chem. Lett. 29 (2019) 1481-1486].
Cited by 0
Semantic Scholar
IL-23 induces regulatory T cell plasticity with implications for inflammatory skin diseases OA
Cited by 56
Semantic Scholar
Abstract LB-A23: Discovery of a potent catalytic p300/CBP inhibitor that targets lineage-specific tumors
Cited by 8
Semantic Scholar
Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours OA
Cited by 9
Semantic Scholar
Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP OA
Cited by 45
Semantic Scholar
Research Topics
PARP inhibition in cancer therapy
(7)
DNA Repair Mechanisms
(6)
Cancer therapeutics and mechanisms
(6)
Protein Degradation and Inhibitors
(6)
Ubiquitin and proteasome pathways
(5)
Affiliations
AbbVie (United States)
Abbott Fund
High Throughput Biology (United States)
University at Buffalo, State University of New York